Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMY1A | P0DUB6 | 3/20 | 0.58 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.58 |
| ▸ | ABL1 | P00519 | 3/20 | 0.55 |
| ▸ | FLT3 | P36888 | 4/20 | 0.52 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.52 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.51 |
| ▸ | ITK | Q08881 | 1/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5952007 | 0.90 | AMY1A (0.58) | AMY1AFGFR1ABL1FLT3PDPK1 | |
| SCHEMBL5952855 | 0.88 | FGFR1 (0.52) | AMY1AFGFR1ABL1FLT3MAP3K8 | |
| SCHEMBL5952152 | 0.86 | TTK (0.58) | FGFR1MAP3K8 | |
| SCHEMBL5952153 | 0.84 | ITK (0.55) | FGFR1ABL1FLT3MAP3K8PDPK1 | |
| SCHEMBL4919287 | 0.82 | FGFR1 (0.66) | FGFR1ABL1FLT3PDPK1ITK | |
| SCHEMBL5951667 | 0.82 | MAP3K8 (0.51) | AMY1AFGFR1ABL1FLT3MAP3K8 | |
| SCHEMBL5953085 | 0.82 | FGFR1 (0.51) | AMY1AFGFR1ABL1FLT3MAP3K8 | |
| SCHEMBL5952142 | 0.82 | ITK (0.62) | AMY1AFGFR1ABL1FLT3MAP3K8 | |
| SCHEMBL6283108 | 0.81 | FGFR1 (0.50) | FGFR1ABL1FLT3MAP3K8PDPK1 | |
| SCHEMBL4912661 | 0.80 | FGFR1 (0.70) | FGFR1ABL1FLT3PDPK1ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | claimed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | claimed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | claimed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | AMY1A 4001/4885FGFR1 583/4885ABL1 55/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | AMY1A 2362/4885FGFR1 254/4885ABL1 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.